Peptide Comparison
TB-500 vs ARA-290
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
ARA-290 has stronger documented evidence (Phase 2) than TB-500 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. TB-500 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| TB-500 | ARA-290 | |
|---|---|---|
| Class | Thymosin β4 fragment; tissue repair | EPO-derived peptide; innate repair receptor (IRR) agonist |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration | Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect |
| Route | SC / IM | SC injection |
| Half-life | Several hrs to days (tissue uptake) | ~2 hrs |
| Dosage (research) | 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly | 2-4 mg SC daily for 28 days (trial protocol) |
| Evidence tier | Anecdotal + Animal Studies | Phase 2 |
| Research depth | 32 indexed | 68 indexed |
| Availability | Compounding Restricted | Investigational |
| Reported risks | WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns | Injection site reactions; Phase 2/3 data limited |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick TB-500 or ARA-290?
ARA-290 has stronger documented evidence (Phase 2) than TB-500 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. TB-500 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between TB-500 and ARA-290?
TB-500 is classed as Thymosin β4 fragment; tissue repair; ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist. Reported mechanism: TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration; ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect. Reported half-life: TB-500, Several hrs to days (tissue uptake); ARA-290, ~2 hrs. Routes in published studies: TB-500, SC / IM; ARA-290, SC injection.
Which has stronger evidence, TB-500 or ARA-290?
ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. TB-500 is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 32 indexed studies. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies.
Which is more accessible, TB-500 or ARA-290?
Neither TB-500 nor ARA-290 is an FDA-approved drug. Catalog status: TB-500, Compounding Restricted; ARA-290, Investigational. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are TB-500 and ARA-290 ever combined?
TB-500 and ARA-290 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…